Phase I Study of Erbitux (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Trial Profile

Phase I Study of Erbitux (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Cetuximab (Primary) ; Irinotecan
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 May 2008 Planned patient number changed from 60 to 48, reported by ClinicalTrials.gov.
    • 15 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
    • 11 Mar 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top